Upgrade to SI Premium - Free Trial

Aldeyra Therapeutics (ALDX)

0.67 -0.06 (8.22%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/12/26)

Latest Headlines

H.C. Wainwright Reiterates Neutral Rating on Aldeyra Therapeutics (ALDX) September 30, 2026 7:20 AM - StreetInsider Aldeyra to challenge FDA rejection of dry eye drug reproxalap September 29, 2026 7:03 AM - StreetInsider Form 8-K Aldeyra Therapeutics, For: Sep 29 September 29, 2026 7:01 AM - SEC Filing Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease September 29, 2026 7:00 AM - BizWire Aldeyra Therapeutics to Host Regulatory Update Webcast September 28, 2026 4:30 PM - BizWire Form SCHEDULE 13G Aldeyra Therapeutics, Filed by: AQR CAPITAL MANAGEMENT LLC August 12, 2026 10:49 AM - SEC Filing Form 10-Q Aldeyra Therapeutics, For: Jun 30 August 6, 2026 4:03 PM - SEC Filing Form 8-K Aldeyra Therapeutics, For: Jul 28 July 30, 2026 5:07 PM - SEC Filing Form SCHEDULE 13G/A Aldeyra Therapeutics, Filed by: BlackRock, Inc. July 27, 2026 4:26 PM - SEC Filing Full Article List